Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

New systems have emerged for diagnosis, staging and response assessment in multiple myeloma (MM). The diagnostic and response criteria recommended are primarily derived from the International Myeloma Working Group, with certain updates and clarifications. The International Staging System is the current standard for staging of myeloma. A new risk stratification model is provided to specifically define high-risk patients who may benefit from novel therapeutic strategies. This paper provides the current criteria for diagnosis, staging, risk stratification and response assessment of MM.

[1]  T. Therneau,et al.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. , 2003, Seminars in oncology.

[2]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[3]  W. Lewis,et al.  Multiple myeloma: diagnosis and treatment. , 2008, American family physician.

[4]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[5]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[6]  P. Loehrer,et al.  International Staging System for Multiple Myeloma , 2006 .

[7]  T. Therneau,et al.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.

[8]  R. Bataille,et al.  Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. , 1983, British journal of haematology.

[9]  Zhaoming Ye,et al.  Solitary plasmacytoma of bone and extramedullary plasmacytoma , 1996 .

[10]  T. Therneau,et al.  POEMS syndrome: definitions and long-term outcome. , 2003, Blood.

[11]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.

[12]  B. Barlogie,et al.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.

[13]  P. Gobbi,et al.  Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance? , 2005, Clinical Cancer Research.

[14]  A. Dispenzieri,et al.  Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. , 2006, Mayo Clinic proceedings.

[15]  A. Rossi,et al.  Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[17]  T. Therneau,et al.  Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system , 2008, Leukemia.

[18]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[19]  R. Bataille,et al.  Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. , 2001, Blood.

[20]  T. Therneau,et al.  Immunoglobulin free light chains and solitary plasmacytoma of bone. , 2006, Blood.

[21]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[22]  B. Barlogie,et al.  Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma , 2002, British journal of haematology.

[23]  T. Therneau,et al.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. , 2008, Blood.

[24]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[25]  M. Beksac,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[26]  P. Richardson,et al.  Clinically relevant end points and new drug approvals for myeloma , 2008, Leukemia.

[27]  M. Dimopoulos,et al.  Solitary plasmacytoma of bone and asymptomatic multiple myeloma. , 2000, Blood.

[28]  Lust,et al.  Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. , 1993, Blood.